Search

Your search keyword '"Williams, Nita"' showing total 40 results
Start Over Author "Williams, Nita"
40 results on '"Williams, Nita"'

3. Update on Comparative Analysis of Immune Reconstitution in HIV-Positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT CTN 0903/AMC-080 and BMT CTN 0803/AMC-071 Trials

Author

Shindiapina, Polina, primary, Pietrzak, Maciej, additional, Seweryn, Michal, additional, McLaughlin, Eric, additional, Zhang, Xiaoli, additional, Makowski, Mat, additional, Ahmed, Elshafa, additional, Pearson, Rebecca, additional, Kitzler, Rhonda, additional, Le-Rademacher, Jennifer G., additional, Little, Richard F, additional, Akpek, Görgün, additional, Ayala, Ernesto, additional, Devine, Steven M., additional, Kaplan, Lawrence D., additional, Noy, Ariela, additional, Popat, Uday R., additional, Hsu, Jack W., additional, Morris, Lawrence E, additional, Mendizabal, Adam, additional, Wachsman, William, additional, Williams, Nita, additional, Sharma, Nidhi, additional, Hofmeister, Craig C, additional, Forman, Stephen J., additional, Navarro, Willis H., additional, Alvarnas, Joseph C., additional, Ambinder, Richard F., additional, Malvestutto, Carlos, additional, Choe, Hannah, additional, Behbehani, Gregory, additional, Lozanski, Gerard, additional, Blaser, Bradley, additional, and Baiocchi, Robert, additional

Published
2023
Full Text
View/download PDF

4. Immune Recovery Following Autologous Hematopoietic Stem Cell Transplantation in HIV-Related Lymphoma Patients on the BMT CTN 0803/AMC 071 Trial

Author

Shindiapina, Polina, primary, Pietrzak, Maciej, additional, Seweryn, Michal, additional, McLaughlin, Eric, additional, Zhang, Xiaoli, additional, Makowski, Mat, additional, Ahmed, Elshafa Hassan, additional, Schlotter, Sarah, additional, Pearson, Rebecca, additional, Kitzler, Rhonda, additional, Mozhenkova, Anna, additional, Le-Rademacher, Jennifer, additional, Little, Richard F., additional, Akpek, Gorgun, additional, Ayala, Ernesto, additional, Devine, Steven M., additional, Kaplan, Lawrence D., additional, Noy, Ariela, additional, Popat, Uday R., additional, Hsu, Jack W., additional, Morris, Lawrence E., additional, Mendizabal, Adam M., additional, Krishnan, Amrita, additional, Wachsman, William, additional, Williams, Nita, additional, Sharma, Nidhi, additional, Hofmeister, Craig C., additional, Forman, Stephen J., additional, Navarro, Willis H., additional, Alvarnas, Joseph C., additional, Ambinder, Richard F., additional, Lozanski, Gerard, additional, and Baiocchi, Robert A., additional

Published
2021
Full Text
View/download PDF

7. AL amyloidosis: The effect of fluorescent in situ hybridization abnormalities on organ involvement and survival

Author

Ozga, Michael, primary, Zhao, Qiuhong, additional, Benson, Don, additional, Elder, Patrick, additional, Williams, Nita, additional, Bumma, Naresh, additional, Rosko, Ashley, additional, Chaudhry, Maria, additional, Khan, Abdullah, additional, Devarakonda, Srinivas, additional, Kahwash, Rami, additional, Vallakati, Ajay, additional, Campbell, Courtney, additional, Parikh, Samir V., additional, Almaani, Salem, additional, Prosek, Jason, additional, Bittengle, Jordan, additional, Pfund, Katherine, additional, LoRusso, Samantha, additional, Freimer, Miriam, additional, Redder, Elyse, additional, Efebera, Yvonne, additional, and Sharma, Nidhi, additional

Published
2020
Full Text
View/download PDF

8. AL Amyloidosis: The Effect of Maintenance Therapy on Autologous Stem Cell Transplantation Outcomes

Author

Ozga, Michael, primary, Zhao, Qiuhong, additional, Benson, Don, additional, Elder, Patrick, additional, Williams, Nita, additional, Bumma, Naresh, additional, Rosko, Ashley, additional, Chaudhry, Maria, additional, Khan, Abdullah, additional, Devarakonda, Srinivas, additional, Kahwash, Rami, additional, Vallakati, Ajay, additional, Campbell, Courtney, additional, Parikh, Samir V., additional, Almaani, Salem, additional, Prosek, Jason, additional, Bittengle, Jordan, additional, Pfund, Katherine, additional, LoRusso, Samantha, additional, Freimer, Miriam, additional, Redder, Elyse, additional, Efebera, Yvonne, additional, and Sharma, Nidhi, additional

Published
2020
Full Text
View/download PDF

9. Comparison of Patient Outcomes with Two Different Formulations of Melphalan As Conditioning Chemotherapy for Autologous Stem Cell Transplantation in Multiple Myeloma

Author

Yucebay, Filiz, primary, Keiter, Ashleigh, additional, Zhao, Qiuhong, additional, Neal, Alison, additional, Williams, Nita, additional, Sharma, Nidhi, additional, Cottini, Francesca, additional, Chaudhry, Maria, additional, Rosko, Ashley, additional, Benson, Don M., additional, Efebera, Yvonne A., additional, Bumma, Naresh, additional, Khan, Abdullah, additional, and Devarakonda, Srinivas, additional

Published
2020
Full Text
View/download PDF

10. 80 - Update on Comparative Analysis of Immune Reconstitution in HIV-Positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT CTN 0903/AMC-080 and BMT CTN 0803/AMC-071 Trials

Author

Shindiapina, Polina, Pietrzak, Maciej, Seweryn, Michal, McLaughlin, Eric, Zhang, Xiaoli, Makowski, Mat, Ahmed, Elshafa, Pearson, Rebecca, Kitzler, Rhonda, Le-Rademacher, Jennifer G., Little, Richard F, Akpek, Görgün, Ayala, Ernesto, Devine, Steven M., Kaplan, Lawrence D., Noy, Ariela, Popat, Uday R., Hsu, Jack W., Morris, Lawrence E, Mendizabal, Adam, Wachsman, William, Williams, Nita, Sharma, Nidhi, Hofmeister, Craig C, Forman, Stephen J., Navarro, Willis H., Alvarnas, Joseph C., Ambinder, Richard F., Malvestutto, Carlos, Choe, Hannah, Behbehani, Gregory, Lozanski, Gerard, Blaser, Bradley, and Baiocchi, Robert

Published
2023
Full Text
View/download PDF

11. A founding locus within the RET proto-oncogene may account for a large proportion of apparently sporadic hirschsprung disease and a subset of cases of sporadic medullary thyroid carcinoma

Author

Borrego, Salud, Wright, Fred A., Fernandez, Raquel M., Williams, Nita, Lopez-Alonso, Manuel, Davuluri, Ramana, Antinolo, Guillermo, and Eng, Charis

Subjects
Hirschsprung's disease -- Physiological aspects, Hirschsprung's disease -- Genetic aspects, Thyroid cancer -- Physiological aspects, Thyroid cancer -- Genetic aspects, Biological sciences
Published
2003

13. AL Amyloidosis: The Prognostic Impact of Maintenance Therapy Following ASCT

Author

Ozga, Michael P., primary, Zhao, Qiuhong, additional, Benson, Don M., additional, Elder, Patrick, additional, Williams, Nita, additional, Bumma, Naresh, additional, Rosko, Ashley, additional, Chaudhry, Maria, additional, Khan, Abdullah, additional, Devarakonda, Srinivas, additional, Kahwash, Rami, additional, Vallakati, Ajay, additional, Campbell, Courtney, additional, Parikh, Samir, additional, Almaani, Salem, additional, Prosek, Jason, additional, Redder, Elyse, additional, Efebera, Yvonne A., additional, and Sharma, Nidhi, additional

Published
2020
Full Text
View/download PDF

14. AL Amyloidosis: The Effects of Maintenance Therapy on Autologous Stem Cell Transplantation Outcomes

Author

Ozga, Michael, primary, Zhao, Qiuhong, additional, Benson, Don M., additional, Elder, Patrick, additional, Williams, Nita, additional, Bumma, Naresh, additional, Rosko, Ashley E., additional, Chaudhry, Maria, additional, Khan, Abdullah Mohammad, additional, Devarakonda, Srinivas, additional, Kahwash, Rami, additional, Vallakati, Ajay, additional, Campbell, Courtney, additional, Parikh, Samir, additional, Almaani, Salem, additional, Prosek, Jason, additional, Redder, Elyse, additional, Efebera, Yvonne A., additional, and Sharma, Nidhi, additional

Published
2019
Full Text
View/download PDF

17. The Effect of Cytogenetic Abnormalities on Organ Involvement and Survival in Patients with AL Amyloidosis

Author

Ozga, Michael, primary, Zhao, Qiuhong, additional, Benson, Don M., additional, Elder, Patrick, additional, Williams, Nita, additional, Bumma, Naresh, additional, Rosko, Ashley E., additional, Chaudhry, Maria, additional, Khan, Abdullah Mohammad, additional, Devarakonda, Srinivas, additional, Kahwash, Rami, additional, Vallakati, Ajay, additional, Campbell, Courtney, additional, Parikh, Samir, additional, Almaani, Salem, additional, Prosek, Jason, additional, Redder, Elyse, additional, Efebera, Yvonne A., additional, and Sharma, Nidhi, additional

Published
2019
Full Text
View/download PDF

20. AL amyloidosis: The effect of fluorescent in situ hybridization abnormalities on organ involvement and survival.

Author

Ozga, Michael, Zhao, Qiuhong, Benson, Don, Elder, Patrick, Williams, Nita, Bumma, Naresh, Rosko, Ashley, Chaudhry, Maria, Khan, Abdullah, Devarakonda, Srinivas, Kahwash, Rami, Vallakati, Ajay, Campbell, Courtney, Parikh, Samir V., Almaani, Salem, Prosek, Jason, Bittengle, Jordan, Pfund, Katherine, LoRusso, Samantha, and Freimer, Miriam

Subjects
FLUORESCENCE in situ hybridization, AMYLOIDOSIS, PROGRESSION-free survival, PROPORTIONAL hazards models, PROGNOSIS
Abstract

Background: Systemic light chain (AL) amyloidosis is a clonal plasma‐cell neoplasm that carries a poor prognosis. Although AL amyloidosis and Multiple Myeloma (MM) can co‐exist and share various cytogenetic chromosomal abnormalities, little is known about Fluorescent in situ hybridization (FISH) and its prognostic relevance in AL amyloidosis. Aim: The study aims to evaluate the most prevalent FISH cytogenetic abnormalities in AL patients as independent prognostic factors, and assess the impact of cytogenetics on the survival of high‐risk cardiac AL patients. Materials & Methods: This retrospective study reviewed 113 consecutive AL patients treated at The Ohio State University (OSU). Patients were divided into subgroups based on FISH data obtained within 90 days of diagnosis. Hyperdiploidy was defined as trisomies of at least 2 chromosomal loci. Primary endpoints were progression free survival (PFS) and overall survival (OS). Kaplan Meier curves were used to calculate PFS and OS. The log‐rank test and Cox proportional hazard models were used to test the equality of survival functions and further evaluate the differences between groups. Results: FISH abnormalities were detected in 76% of patients. Patients with abnormal FISH trended toward lower overall survival (OS) (p=0.06) and progression free survival (PFS) (p=0.06). The two most prevalent aberrations were translocation t(11;14) (39%) and hyperdiploidy‐overall (38%). Hyperdiploidy‐overall was associated with worsening PFS (p=0.018) and OS (p=0.03), confirmed in multivariable analysis. Patients with del 13q most frequently had cardiac involvement (p=0.006) and was associated with increased bone marrow plasmacytosis (p=0.02). Cardiac AL patients with no FISH abnormalities had much improved OS (p=0.012) and PFS (p=0.018) Conclusions: Our findings ultimately reveal the association of hyperdiploidy on survival in AL amyloidosis patients, including the high‐risk cardiac AL population. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

21. A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma

Author

Calero Miguel, Plass Christoph, Williams Nita, Bekaii-Saab Tanios, and Eng Charis

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Several studies showed that gain-of-function somatic mutations affecting the catalytic domain of EGFR in non-small cell lung carcinomas were associated with response to gefitinib and erlotinib, both EGFR-tyrosine kinase inhibitors. In addition, 4% of non-small cell lung carcinomas were shown to have ERBB2 mutations in the kinase domain. In our study, we sought to determine if similar respective gain-of-function EGFR and ERBB2 mutations were present in hepatoma and/or biliary cancers. Methods We extracted genomic DNA from 40 hepatoma (18) and biliary cancers (22) samples, and 44 adenocarcinomas of the lung, this latter as a positive control for mutation detection. We subjected those samples to PCR-based semi-automated double stranded nucleotide sequencing targeting exons 18–21 of EGFR and ERBB2. All samples were tested against matched normal DNA. Results We found 11% of hepatoma, but no biliary cancers, harbored a novel ERBB2 H878Y mutation in the activating domain. Conclusion These newly described mutations may play a role in predicting response to EGFR-targeted therapy in hepatoma and their role should be explored in prospective studies.

Published
2006
Full Text
View/download PDF

22. Most multiple myeloma patients have low testosterone

Author

John, Sonya, primary, Sharma, Nidhi, additional, Sborov, Douglas W., additional, Williams, Nita, additional, Jones, Desirée, additional, Benson, Don M., additional, Efebera, Yvonne A., additional, Rosko, Ashley E., additional, Vincent, Jennifer, additional, and Hofmeister, Craig C., additional

Published
2018
Full Text
View/download PDF

24. G-CSF improves safety when you start the day after autologous transplant in multiple myeloma

Author

Sborov, Douglas W., primary, Cho, Yu Kyoung, additional, Cottini, Francesca, additional, Hade, Erinn M., additional, Lamprecht, Misty, additional, Tackett, Karen, additional, Sharma, Nidhi, additional, Williams, Nita, additional, Li, Junan, additional, Devine, Steven, additional, Poi, Ming, additional, Phelps, Mitch A., additional, and Hofmeister, Craig C., additional

Published
2017
Full Text
View/download PDF

31. A phase 1 study of vorinostat maintenance after autologous transplant in high-risk lymphoma

Author

Hofmeister, Craig C., primary, Williams, Nita, additional, Geyer, Susan, additional, Hade, Erinn M., additional, Bowers, Mindy A., additional, Earl, Christian T., additional, Vaughn, John, additional, Bingman, Anissa, additional, Humphries, Kristina, additional, Lozanski, Gerard, additional, Baiocchi, Robert A., additional, Jaglowski, Samantha M., additional, Blum, Kristie, additional, Porcu, Pierluigi, additional, Flynn, Joseph, additional, Penza, Sam, additional, Benson, Don M., additional, Andritsos, Leslie A., additional, and Devine, Steven M., additional

Published
2014
Full Text
View/download PDF

32. Most multiple myeloma patients have low testosterone.

Author

John, Sonya, Sharma, Nidhi, Sborov, Douglas W., Williams, Nita, Jones, Desirée, Benson, Don M., Efebera, Yvonne A., Rosko, Ashley E., Vincent, Jennifer, and Hofmeister, Craig C.

Subjects
MELPHALAN, MUSCLE cramps, MULTIPLE myeloma, TESTOSTERONE
Abstract

The article presents a study which measures the serum testosterone level of patients with multiple myeloma. Information is offered on the National Health and Nutrition Examination Survey conducted for determining the health status of adults and children in the U.S. A table is presented depicting the correlation among testosterone and other factors in multiple myeloma patients.

Published
2019
Full Text
View/download PDF

34. A phase 1 study of vorinostat maintenance after autologous transplant in high-risk lymphoma.

Author

Hofmeister, Craig C., Williams, Nita, Geyer, Susan, Hade, Erinn M., Bowers, Mindy A., Earl, Christian T., Vaughn, John, Bingman, Anissa, Humphries, Kristina, Lozanski, Gerard, Baiocchi, Robert A., Jaglowski, Samantha M., Blum, Kristie, Porcu, Pierluigi, Flynn, Joseph, Penza, Sam, Benson, Don M., Andritsos, Leslie A., and Devine, Steven M.

Subjects
*LYMPHOMAS, *AUTOGRAFTS, *CANCER treatment, *VACCINES, *DEACETYLASES
Abstract

Only a minority of patients with high risk lymphoma will be cured with autologous transplant, so maintenance with vorinostat, an oral agent with activity in relapsed lymphoma, was studied starting day + 60 for 21 consecutive days followed by a week off for up to 11 cycles. Twenty-three patients with lymphoma were treated. Ten patients completed the full 11 -cycle treatment plan per protocol, four patients were removed due to progressive disease and seven withdrew or were removed from the study due to toxicities. Despite Prevnar vaccine administration every 2 months for three injections, the mean antibody concentration never reached protective levels (>0.35 pg/mL). Fatigue and functional well-being measured by Brief Fatigue Inventory and Functional Assessment of Cancer Therapy-General improved significantly from cycle 1 to cycle 7, but depression scores from the Center for Epidemiologic Studies Depression scale did not change. Given the toxicities observed, this broad-spectrum deacetylase inhibitor at this schedule is not optimal for prolonged maintenance therapy. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

37. Analysis of the Molecular Quality of Human Tissues

Author

Jewell, Scott D., primary, Srinivasan, Mythily, additional, McCart, Linda M., additional, Williams, Nita, additional, Grizzle, William H., additional, LiVolsi, Virginia, additional, MacLennan, Greg, additional, and Sedmak, Daniel D., additional

Published
2002
Full Text
View/download PDF

38. Shingles Occurs in Only 0.5% of Myeloma Patients on Any Dose of Antiviral Prophylaxis

Author

Chu, Jacqueline, Hussaini, Syed Basir, Sharma, Nidhi, Williams, Nita, Benson, Don M, Rosko, Ashley E, Efebera, Yvonne A, and Hofmeister, Craig C

Abstract

Background:CDC estimates that approximately 30% of persons in the U.S. will experience shingles during their lifetimes (http://www.cdc.gov/shingles/surveillance.html). The incidence among people 60 years of age and older is about 10 cases per 1,000 U.S. population annually. With a median age of 70 y.o. and frequent proteasome inhibitor use (Kim SJ et al, Clinical lymphoma & myeloma,2008), multiple myeloma patients often receive scheduled prophylaxis for shingles with acyclovir or valacyclovir; however, there are currently no guidelines on the appropriate dosage for the prevention of shingles. Recent studies have used antiviral doses of acyclovir 2400mg/day to as low as acyclovir 200 mg/day to prevent shingles (Pour L et al., Clinical lymphoma & myeloma2009; Kim SJ et al., Jpn J Clin Oncol2011), but doses of 200-800 mg acyclovir per day are common in clinical practice. By reviewing all myeloma patients treated over the last 6 years, we hypothesized that a less than 1% failure rate can be achieved using the equivalent of acyclovir 400 mg twice daily in a patient with normal renal function. In addition, based on the findings of a recent study (Dosani T et al., Blood, 2017), which demonstrated that ALC/AMC ratio at time of multiple myeloma diagnosis can be used as an indicator of baseline immune status, we hypothesized in this present study that multiple myeloma patients who had shingles have a significantly lower ALC/AMC ratio on average than patients who did not have shingles.

Published
2017
Full Text
View/download PDF

39. B-Cell Lymphoma Patients Have a 10% Risk of Shingles, 7% in Cutaneous T-Cell Lymphoma

Author

Hussaini, Syed Basir, Chu, Jacqueline, Williams, Nita, Sharma, Nidhi, Benson, Don M, Rosko, Ashley E, Efebera, Yvonne A, and Hofmeister, Craig C

Abstract

Background:Patients with lymphoma can be immunosuppressed from the disease, treatment or both. One indicator of cellular mediated immunity is reactivation of Varicella Zoster (VZV), a painful viral infection estimated to occur to 30% of U.S. population during a lifetime and associated with a particularly morbid post-herpetic neuralgia. Bortezomib and dexamethasone have been shown to be correlated with increased rates of varicella zoster and other viral infections (Kim SJ et al, Clinical lymphoma & myeloma,2008). Autologous stem cell transplant depletes cellular- and humoral-immunity (Kamber C et al, BMT, 2015). While the main risk factor for VZV reactivation is age (Harpaz R, MMWR Recomm Rep, 2008), the underlying malignancy might play a large role in the risk of VZV reactivation. There is little data comparing the proportion of VZV in multiple myeloma (MM) with other indolent B and T-cell lymphomas. The purpose of this study is to compare varicella infection in MM patients with chronic lymphocytic leukemia (CLL), cutaneous T-cell lymphoma (CTCL), and follicular lymphoma (FL). Given that VZV is a relatively common infection in patients with MM, we hypothesized that varicella reactivation in MM patients occurs at a higher rate than in patients with CLL, CTCL, or FL.

Published
2017
Full Text
View/download PDF

40. The Multiple Myeloma Research Consortium (MMRC): A Model For Accelerating Development Of Novel Therapies For Multiple Myeloma

Author

Harrison, Beverly, Anderson, Kenneth C., Raje, Noopur, Richardson, Paul, Warren, Diane, Chari, Ajai, Jagannath, Sundar, La, Lisa, Berdeja, Jesus, Zimlich, Meredith, Fay, Joseph W., Powell, Sheila, Hofmeister, Craig C, Williams, Nita, Jakubowiak, Andrzej J., Zimmerman, Todd M., McDonnell, Kathryn, Krishnan, Amrita Y., Duarte, Lupe, Kumar, Shaji K, Birgin, Ann, Lonial, Sagar, Baron, Kenisha, Martin, Thomas, Wolf, Jeffrey L, Pelle-Day, Geraldine, Auerback, Glenna, Orloff, Gregory, Hodge, Nikki, Reece, Donna E, Trudel, Suzanne, Gul, Engin, Roy, Vivek, Maharaj, Michele, Siegel, David S., Aleman, Adolfo, Stewart, A. Keith, Hagerty, Rachel, Talpaz, Moshe, Collins, Roxane, Vij, Ravi, Fiala, Mark A., Zonder, Jeffrey, Pregja, Silva, Goldberg, Sharon, Levy, Joan, Dietz, Karen, Capone, Walter, Auclair, Daniel, Young, Anne Quinn, and Giusti, Kathy

Abstract

The MMRC is a non-profit, disease-focused consortium dedicated to accelerating the development of novel compounds and combination treatments for multiple myeloma through a unique industry/institutional partnership.  Founded in 2004, the MMRC currently includes 16 N. American centers with expertise in multiple myeloma and a primary focus on rapid initiation and completion of Phase 1 and 2 clinical trials.  Eight of the 16 member institutions are National Cancer Institute (NCI)-designated cancer centers.  A number of critical business processes have been implemented within the MMRC to improve trial performance, from funding of dedicated project managers at member institutions to incorporation of a clinical trial management system and the development of standard contracts acceptable to all member institutions.  Trials conducted within the Consortium are carefully monitored and tracked for operational performance using industry-standard metrics.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results